Clinical Trial Update: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated adding antidepressants to fingolimod in patients with relapsing-remitting multiple sclerosis and depression; the study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Antidepressants (unspecified) (Antidepressants)
• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Depression, Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2014-09-25